Fiche publication
Date publication
mai 2023
Journal
Cell death & disease
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BETTAIEB Ali
,
Dr PLENCHETTE Stéphanie
Tous les auteurs :
Meunier M, Yammine A, Bettaieb A, Plenchette S
Lien Pubmed
Résumé
Nitroglycerin (NTG) is a prodrug that has long been used in clinical practice for the treatment of angina pectoris. The biotransformation of NTG and subsequent release of nitric oxide (NO) is responsible for its vasodilatating property. Because of the remarkable ambivalence of NO in cancer disease, either protumorigenic or antitumorigenic (partly dependent on low or high concentrations), harnessing the therapeutic potential of NTG has gain interest to improve standard therapies in oncology. Cancer therapeutic resistance remains the greatest challenge to overcome in order to improve the management of cancer patients. As a NO releasing agent, NTG has been the subject of several preclinical and clinical studies used in combinatorial anticancer therapy. Here, we provide an overview of the use of NTG in cancer therapy in order to foresee new potential therapeutic avenues.
Mots clés
Humans, Nitroglycerin, pharmacology, Angina Pectoris, Nitric Oxide, Neoplasms, drug therapy
Référence
Cell Death Dis. 2023 05 12;14(5):323
